Related Experiment Video
Updated: May 12, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical
A Kruczynski1, A Pillon, L Créancier
1Department of Research, Experimental Oncology Research Center, Pierre Fabre Research Institute, Toulouse, France.
Abstract:
Chemotherapy remains mainly used for the treatment of acute myeloid leukemia (AML). However, in the past 3 decades limited progress has been achieved in improving the long-term disease-free survival. Therefore the development of more effective drugs for AML represents a high level of priority. F14512 combines an epipodophyllotoxin core targeting topoisomerase II with a spermine moiety introduced as a cell delivery vector. The polyamine moiety facilitates F14512 selective uptake by tumour cells via the polyamine transport system, a machinery overactivated in cancer cells. F14512 has been characterized as a potent drug candidate and is currently in Phase I clinical trials. Here, we demonstrated marked survival benefit and therapeutic efficacy of F14512 treatments in a series of human AML models, established either from AML cell lines or from patient AML samples. Furthermore, we reported in vitro synergistic anti-leukemic effects of F14512 in combination with cytosine arabinoside (Ara-C), doxorubicin, gemcitabine, bortezomib or SAHA. In vivo combination of suboptimal doses of F14512 with Ara-C also resulted in enhanced anti-leukemic activity. We further showed that F14512 triggered both senescence and apoptosis in vivo in primary AML models, but not autophagy. Overall, these results support the clinical development in onco-hematology of this novel promising drug candidate.
Insights
F14512 shows significant survival benefits and therapeutic efficacy in acute myeloid leukemia (AML) models. This novel drug candidate, targeting topoisomerase II, also demonstrates synergistic effects with other chemotherapies, supporting its clinical development.
Area of Science:
- Oncology
- Pharmacology
- Hematology
Background:
- Chemotherapy for acute myeloid leukemia (AML) has seen limited progress in long-term survival.
- Developing more effective AML treatments is a high priority.
Purpose of the Study:
- To evaluate the therapeutic efficacy of F14512 in human AML models.
- To investigate the synergistic effects of F14512 in combination with other anti-leukemic agents.
Main Methods:
- F14512, a topoisomerase II inhibitor with a spermine delivery vector, was tested in human AML cell lines and patient-derived samples.
- In vitro and in vivo studies assessed F14512 efficacy alone and in combination with standard chemotherapies (Ara-C, doxorubicin, gemcitabine, bortezomib, SAHA).
- Mechanisms of action, including apoptosis, senescence, and autophagy, were analyzed.
Main Results:
- F14512 demonstrated a marked survival benefit and therapeutic efficacy in various human AML models.
- Synergistic anti-leukemic effects were observed in vitro when F14512 was combined with other agents.
- In vivo combination therapy with suboptimal F14512 and Ara-C enhanced anti-leukemic activity.
- F14512 induced senescence and apoptosis in vivo, but not autophagy, in primary AML models.
Conclusions:
- F14512 exhibits potent anti-leukemic activity and survival benefits in AML models.
- Combination therapies involving F14512 show enhanced efficacy.
- These findings support the ongoing clinical development of F14512 for onco-hematology.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...